ライフサイエンスコーパス: epratuzumab

1 ing effective targeting of leukemic cells by epratuzumab.

2 rafts was also observed after treatment with epratuzumab.

3 ed lesions were visualized with (111)In-DOTA-epratuzumab.

4 ify the maximum tolerated dose of (90)Y-DOTA-epratuzumab.

5 Epratuzumab, a humanized anti-CD22 antibody, is currentl

6 asparagine (Asn), with framework regions of epratuzumab, a humanized anti-CD22 antibody.

7 quantifying changes in CD22 expression after epratuzumab administration.

8 a), and 22-20, a bispecific HexAb comprising epratuzumab and 4 Fabs of veltuzumab, were previously sh

9 bodies with alternate binding sites, such as epratuzumab and HU1D10, and bispecific antibodies that c

10 Fifty-five patients received epratuzumab and were assessable for safety; 51 patients

11 he safety, efficacy, and pharmacokinetics of epratuzumab (anti-CD22 humanized monoclonal antibody) in

12 unlabeled humanized antibodies against CD22 (epratuzumab), CD74 (milatuzumab), or veltuzumab.

13 rrently in development, including rituximab, epratuzumab, diphtheria toxin-single chain Fv (DC2219),

14 Epratuzumab (E) is an unlabeled anti-CD22 monoclonal ant

15 (bsAbs) derived from veltuzumab (v-mab) and epratuzumab (e-mab).

16 The whole-body half-life for (90)Y-DOTA-epratuzumab estimated from (111)In-DOTA-epratuzumab scin

17 ic HexAb comprising veltuzumab and 4 Fabs of epratuzumab (humanized anti-CD22 IgG1kappa), and 22-20,

18 ed from veltuzumab (humanized anti-CD20) and epratuzumab (humanized anti-CD22) and evaluated in vitro

19 a pretherapy imaging study with (111)In-DOTA-epratuzumab IgG (0.75 mg/kg), followed about 1 wk later

20 n by the finding that SLE patients receiving epratuzumab immunotherapy had significantly reduced CD19

21 of CD19 are implicative for the efficacy of epratuzumab in autoimmune diseases because elevated CD19

22 Epratuzumab is a humanized anti-CD22 monoclonal, which h

23 compared with 35.2 +/- 7.0 h for (90)Y-DOTA-epratuzumab (n = 22).

24 Thus, epratuzumab offers a promising option for CD22-targeted

25 Patients received one cycle of (90)Y-DOTA-epratuzumab on days 1 and 8 (give or take 2 days) succes

26 pendent and results from their transfer from epratuzumab-opsonized B cells to FcgammaR-expressing mon

27 Treatment with epratuzumab plus standard reinduction chemotherapy is fe

28 Here we report for the first time that epratuzumab promptly induces a marked decrease of CD22 (

29 (90)Y-DOTA-epratuzumab radioimmunotherapy is well tolerated.

30 anti-CD22 epratuzumab tetraxetan ((90)Y-DOTA-epratuzumab) radioimmunotherapy in refractory or relapse

31 nts uniformly treated on a clinical trial of epratuzumab/rituximab-CHOP.

32 DOTA-epratuzumab estimated from (111)In-DOTA-epratuzumab scintigraphy was 58.3 +/- 4.7 h (n = 20), wi

33 ), followed about 1 wk later with (90)Y-DOTA-epratuzumab starting at a dose level of 0.185 GBq/m(2) (

34 nd efficacy of yttrium-90-labelled anti-CD22 epratuzumab tetraxetan ((90)Y-DOTA-epratuzumab) radioimm

35 wo doses of 15 mCi/m(2) (555 MBq/m(2)) (90)Y-epratuzumab tetraxetan administered 1 week apart.

36 ted radioimmunotherapy using anti-CD22 (90)Y-epratuzumab tetraxetan as consolidation after front-line

37 : Fractionated radioimmunotherapy with (90)Y-epratuzumab tetraxetan might be appropriate for response

38 Fractionated radioimmunotherapy with (90)Y-epratuzumab tetraxetan might be appropriate for response

39 of CD22 is expected from internalization by epratuzumab, the concurrent and prominent reduction of C

40 Of interest are epratuzumab, the interferon antagonists and peptide-base

41 process may be beneficial in the context of epratuzumab treatment of autoimmune diseases.

42 regimens have acceptable toxicity, and that epratuzumab warrants further evaluation as an adjunct to

43 e effective blood half-life for (111)In-DOTA epratuzumab was 36.1 +/- 7.9 h (n = 25) compared with 35

44 Epratuzumab was administered intravenously at 120 to 1,0

45 An anti-antibody response to epratuzumab was detected by an enzyme-linked immunosorbe

46 Epratuzumab was well tolerated at up to 1,000 mg/m2/wk (

47 Epratuzumab was well tolerated, with no dose-limiting to

48 ion-grafted (humanized) anti-CD22 mAb, hLL2 (epratuzumab), was conjugated to 3 different chelating ag

49 nd (90)Y-labeled humanized antibody to CD22, epratuzumab, was studied in patients with non-Hodgkin's

50 Serum concentrations of epratuzumab were determined before and 30 minutes after

51 doses of up to 0.370 GBq/m(2) of (90)Y-DOTA-epratuzumab were tolerated with standard support measure

52 The full-dose combination of epratuzumab with rituximab was well tolerated and had si